Pharmacology News and Research

Latest Pharmacology News and Research

Three leading scientists gather to discuss Improved Strategies for Pre-clinical Cardiac Testing

Three leading scientists in the field of cardiac safety in pre-clinical drug development are gathering to discuss Improved Strategies for Pre-clinical Cardiac Testing in a free webinar on June 23 at 11:00 a.m. EDT, sponsored by the Drug Safety Council.

22 Jun 2010

Diabetes control in COPD patients could improve outcomes, length of hospital stays and risk of death

A new study in the journal Respirology reveals that patients with diabetes who are hospitalized with acute exacerbations of chronic obstructive pulmonary disease (COPD) experience longer time in the hospital and are also at an increased risk of death, compared to those without diabetes.

22 Jun 2010

Star Scientific seeks FDA approval of Stonewall-BDL as "modified risk tobacco product"

Star Scientific, Inc. announced that on Friday, June 18 the company filed an application with the Food & Drug Administration for approval to market Stonewall-BDL™ as a "modified risk tobacco product" under the Family Smoking Prevention and Tobacco Control Act of 2009. This is Star's second such application to the Tobacco Products Center of the FDA, which has been established to oversee all aspects of tobacco regulation outlined in the 2009 Act.

22 Jun 2010

Celator announces expansion of research agreement with Cephalon

Celator Pharmaceuticals today announced that it has expanded its research agreement with Cephalon, Inc.. The research agreement provides for the utilization of Celator's proprietary technology in an ongoing drug development and life-cycle management program at Cephalon.

22 Jun 2010

New Zealanders sucking in more nicotine per cigarette than most other smokers worldwide

Smokers in New Zealand are taking in more nicotine than Australians says a new study. The study found that smokers there have a distinct preference for high nicotine containing brands of cigarettes and have the greatest average amount of tar exposure out of 5,703 smokers in eight countries. Where Australians took 1.36mg of nicotine per cigarette, New Zealanders took in 1.62mg.

21 Jun 2010

Additional positive data from Ardea Biosciences' RDEA594 Phase 2 program presented at EULAR

Ardea Biosciences, Inc. announced that additional positive data from its Phase 2 program for RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, are being presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy. RDEA594, a first-in-class selective inhibitor of the URAT1 transporter, treats the underlying cause of gout by increasing the excretion of uric acid in order to bring the body's levels of uric acid into a normal range.

18 Jun 2010

9th INT'L BIO FORUM & BIO EXPO JAPAN from June 30 - July 2, 2010

9th INT'L BIO FORUM & BIO EXPO JAPAN, organized by Reed Exhibitions Japan, will come back again as Asia's largest bio-event from June 30 - July 2, 2010. "Gene diagnosis" is one of the featured topics for this year.

18 Jun 2010

Study validates NT-proBNP as strong indicator for cardiovascular risk in arthritis patients

The role of N-terminal pro-B-type natriuretic peptide (NT-proBNP, a protein thought to be a regulator of cardiovascular function) as a robust, non-invasive predictor of cardiovascular (CV) risk in patients with arthritis taking cyclooxygenase inhibitors has been reinforced by the results of a multinational study presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

18 Jun 2010

Ricerca announces services under U.S. DEA license

Ricerca Biosciences, an industry-leading, integrated preclinical contract research organization (CRO) providing services to the chemical and biopharmaceutical industries, is pleased to announce services it can now provide under its United States Drug Enforcement Administration (DEA) license.

18 Jun 2010

Positive Phase I results from ChemoCentryx CCX354 study for RA presented at EULAR

ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).

17 Jun 2010

Patients prescribed NSAIDs also receive appropriate measures to prevent UGI problems: Study

Four out of ten high-risk patients prescribed nonsteroidal anti-inflammatory drugs also received appropriate measures to prevent upper-gastrointestinal problems, but the remainder did not receive adequate protection, according to a study in the June issue of Alimentary Pharmacology and Therapeutics.

17 Jun 2010

Research findings could lead to less invasive treatments for ALL

A team of researchers from the Institute for Research in Immunology and Cancer of the Universit- de Montr-al have defined for the first time the mechanism behind three cancer-causing genes in acute lymphoblastic leukemia. Published in the journal Genes and Development, the findings offer insight on the complex interaction between the genes and their contributions to leukemia, thereby providing the foundation for the design of targeted therapies.

17 Jun 2010

Oncodesign announces technology license agreement with Janssen Pharmaceutica

Oncodesign Biotechnology(R) announced today that it has signed a licensing agreement with Janssen Pharmaceutica NV (hereinafter Janssen) related to Janssen’s macrocyclic chemistry technology. Oncodesign will have exclusive access to this technology for six years.

16 Jun 2010

How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation

Type 2 diabetes is characterized by unsatisfactory levels of glycated hemoglobin (HbA1c) for extended periods. An article published in the May 2010 edition of Postgraduate Medicine reports a proposal to shorten the total time spent with uncontrolled hyperglycemia by minimizing the number of steps along the treatment-intensification ladder. In doing so, patients would decrease their exposure to hyperglycemia and potentially improve long-term outcomes.

16 Jun 2010

Stress-related psychiatric disorders more common among women: Study

There may be a biological reason why depression and other stress-related psychiatric disorders are more common among women compared to men. Studying stress signaling systems in animal brains, neuroscience researchers found that females are more sensitive to low levels of an important stress hormone and less able to adapt to high levels than males.

16 Jun 2010

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced results from a pre-clinical study showing that calcipotriene 0.005% and betamethasone dipropionate 0.064%, when formulated with NexACT®, results in a topical treatment which shows bioequivalecy in efficacy to Talconex®, one of the leading topical treatments marketed for patients with mild to moderate psoriasis.

16 Jun 2010

Disorder in degradation of proteins and other macromolecules in cells leads to serious diseases

The degradation of proteins and other macromolecules in cells is vital to survival. Disruption of this process can result in serious disease. The research group of Professor Thomas Jentsch (Leibniz Institute for Molecular Pharmacology, FMP/ Max Delbr-ck Center for Molecular Medicine, MDC, Berlin-Buch) has now succeeded in identifying an essential cellular process necessary for the transport and degradation of macromolecules in endosomes and lysosomes, respectively.

16 Jun 2010

Depression and other stress-related psychiatric disorders in women may have biological basis: Research

15 Jun 2010

PAREXEL, Bristol-Myers Squibb establish strategic partnership in clinical development

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that Bristol-Myers Squibb, a global biopharmaceutical company, has established a strategic partnership with PAREXEL to enable greater effectiveness in clinical development.

From Parexel 14 Jun 2010

Asterand subsidiary BioSeek signs agreement with Amylin

Asterand plc, a leading provider of human tissue and human tissue-based research services to pharmaceutical and biotechnology companies engaged in drug discovery, today announces that its subsidiary BioSeek, LLC, a pioneer in the application of predictive human biology to drug discovery, has signed a one-year collaboration agreement with Amylin Pharmaceuticals, Inc.

14 Jun 2010

Pharmacology News and Research

Latest Pharmacology News and Research

Three leading scientists gather to discuss Improved Strategies for Pre-clinical Cardiac Testing

Diabetes control in COPD patients could improve outcomes, length of hospital stays and risk of death

Star Scientific seeks FDA approval of Stonewall-BDL as "modified risk tobacco product"

Celator announces expansion of research agreement with Cephalon

New Zealanders sucking in more nicotine per cigarette than most other smokers worldwide

Additional positive data from Ardea Biosciences' RDEA594 Phase 2 program presented at EULAR

9th INT'L BIO FORUM & BIO EXPO JAPAN from June 30 - July 2, 2010

Study validates NT-proBNP as strong indicator for cardiovascular risk in arthritis patients

Ricerca announces services under U.S. DEA license

Positive Phase I results from ChemoCentryx CCX354 study for RA presented at EULAR

Patients prescribed NSAIDs also receive appropriate measures to prevent UGI problems: Study

Research findings could lead to less invasive treatments for ALL

Oncodesign announces technology license agreement with Janssen Pharmaceutica

How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation

Stress-related psychiatric disorders more common among women: Study

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

Disorder in degradation of proteins and other macromolecules in cells leads to serious diseases

Depression and other stress-related psychiatric disorders in women may have biological basis: Research

PAREXEL, Bristol-Myers Squibb establish strategic partnership in clinical development

Asterand subsidiary BioSeek signs agreement with Amylin

Pittcon Highlights: Pharmaceutical & Biologic eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Pharmacology News and Research

Latest Pharmacology News and Research

Pittcon Highlights: Pharmaceutical & Biologic eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in